Cargando…
Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models
Despite the use of intensive multimodality therapy, the majority of high-risk neuroblastoma (NB) patients do not survive. Without significant improvements in delivery strategies, anticancer agents used as a first-line treatment for high-risk tumors often fail to provide clinically meaningful results...
Autores principales: | Alferiev, Ivan S., Guerrero, David T., Soberman, Danielle, Guan, Peng, Nguyen, Ferro, Kolla, Venkatadri, Fishbein, Ilia, Pressly, Blake B., Brodeur, Garrett M., Chorny, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836113/ https://www.ncbi.nlm.nih.gov/pubmed/35163672 http://dx.doi.org/10.3390/ijms23031752 |
Ejemplares similares
-
Poloxamer‐linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high‐risk neuroblastoma with primary and acquired chemoresistance
por: Alferiev, Ivan S., et al.
Publicado: (2022) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti, Isabella, et al.
Publicado: (2020) -
A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model
por: Orienti, Isabella, et al.
Publicado: (2019) -
Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma
por: Higashi, Mayumi, et al.
Publicado: (2015) -
Intraprocedural endothelial cell seeding of arterial stents via biotin/avidin targeting mitigates in-stent restenosis
por: Alferiev, Ivan S., et al.
Publicado: (2022)